The Bausch + Lomb Trulign toric accommodating posterior chamber ocular lens has received premarket approval from the Ophthalmic Devices Panel of the FDA, according to a Medscape report.
Ophthalmology
Researchers of The Schepens Eye Research Institute of Massachusetts Eye and Ear in Boston and the Harvard Medical School ophthalmology department have conducted a study that shows Ranibizumab as a promising prevention of proliferative vitreoretinopathy.
Bausch + Lomb's VICTUS Femtosecond laser platform has received CE Mark for corneal incisions made during cataract surgery, according to a Laser Focus World report.
NovaBay Pharmaceuticals, an Emeryville, Calif.-based biotechnology company, has enrolled its first patients in a global Phase 2b clinical trial designed to test its Auriclosene Ophthalmic Solution as a treatment for a highly contagious form of pink-eye.
The FDA has granted Bausch + Lomb approval for PROLENSA, its anti-inflammatory prescription eye drop for patients that have undergone cataract surgery.
Advertisement
Aiello Eye Institute in Yuma, Ariz., has announced that it has added optical services to the LASIK, cataract surgery and various ophthalmology options offered at its Foothills location.
Colorado University School of Medicine in Aurora has created the Sue Anschutz-Rodgers Endowed Chair in Retinal Diseases in honor of a $2 million donation, according to a Denver Journal report.
Aerie Pharmaceuticals has named David Epstein, MD, a board-certified ophthalmologist, as chairman of the company's scientific advisory board.
The LENSAR Laser System, designed to help surgeons perform precise corneal and arcuate incisions during refractive cataract surgery, has earned FDA 510(k) clearance.
InSite Vision has earned $15 million for future royalties of Besivance, its pink-eye antibacterial eye drop, according to a San Francisco Business Times report.